Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies
Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and
phase
COVID-19 vaccine by Reynolds subsidiary advances to scientific trial phase | Neighborhood
Kentucky Bioprocessing jobs receiving success from the research by mid-2021. “Kentucky Bioprocessing has spent just